Literature DB >> 32533094

Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection.

Chunmei Yang1,2, Mixue Xie1,2, Kaifeng Zhang2, Hui Liu3, Aibin Liang4, Ken H Young5, Wenbin Qian6,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32533094     DOI： 10.1038/s41375-020-0913-y

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

Review 1.  Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.

Authors:  Kitsada Wudhikarn; Miguel-Angel Perales
Journal:  Bone Marrow Transplant       Date:  2022-07-15       Impact factor: 5.174

2.  [The Chinese consensus for the CAR-T cell therapy in multiple myeloma (2022 version)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-04-14

3.  [The consensus on the prophylaxis and treatment of HBV reactivation in B or plasma cell-directed CAR-T cell therapy(2021)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-06-14

4.  [How I manage B cell lymphoma patients treated with CD19 specific CAR-T cell throughout whole-process management].

Authors:  W B Qian; H Liu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-03-14

5.  Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy.

Authors:  Chunmei Yang; Wen Lei; Hongqiong Xie; Gongqiang Wu; Juying Wei; Aibin Liang; Wenbin Qian
Journal:  Onco Targets Ther       Date:  2020-11-25       Impact factor: 4.147

6.  Protective Role of Rheumatic Diseases Against Hepatitis B Virus Infection and Human Leukocyte Antigen B27 Highlighted.

Authors:  Junna Ye; Peilin Xie; Zhuochao Zhou; Yue Sun; Fan Wang; Yijun You; Jialin Teng; Chengde Yang; Xinxin Zhang; Yue Han
Journal:  Front Med (Lausanne)       Date:  2022-02-10

7.  Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.

Authors:  Zhihui Li; Fanqiao Meng; Jing Li; Tong Wu
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786

Review 8.  Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Yibo Wu; He Huang; Yi Luo
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561

9.  Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.

Authors:  Ping Li; Lili Zhou; Shiguang Ye; Wenjun Zhang; Junbang Wang; Xiaochen Tang; Jie Liu; Yangyang Xu; Wenbin Qian; Aibin Liang
Journal:  Front Immunol       Date:  2021-07-15       Impact factor: 7.561

10.  Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy.

Authors:  Yaxian Ma; Li Yang; Yuhan Bao; Yang Yang; Liting Chen; Miao Zheng
Journal:  Front Immunol       Date:  2021-10-08       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.